Abbott Laboratories Faces Challenges Amid Legal Pressure and Market Conditions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 29 2024
0mins
Should l Buy ABT?
Abbott Laboratories (ABT) shares have hit a 52-week low, reflecting ongoing challenges in the market despite the Nasdaq-100 and S&P 500 showing gains.
The stock's decline is attributed to a combination of factors, including a recent $495 million verdict upheld by a Missouri appeals court, which has added legal pressure and contributed to a 5.5% drop from April 29 to May 6. Additionally, the company's slow growth in its nutrition and diagnostics segments, with only 3.7% comparable sales growth in Q1, has impacted investor confidence, leading to a significant year-to-date decline of 30%.
Despite these challenges, 21 out of 28 Wall Street analysts still rate Abbott as a buy or higher, indicating a belief in its long-term value. The company's strong history of dividend increases and recent acquisition of Exact Sciences for $21 billion, which aims to enhance its product offerings, may provide a foundation for recovery in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 87.010
Low
136.00
Averages
148.11
High
169.00
Current: 87.010
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Laboratories Q4 2025 Financial Results Analysis
- Revenue Growth: Abbott reported total net sales of $11.459 billion in Q4 2025, reflecting a 4.4% increase, while organic growth reached 3.8% after excluding declining COVID-19 testing sales, indicating resilience in its medical device segment.
- Profitability Improvement: Adjusted diluted EPS rose 12% to $1.50, meeting market expectations, with operating margin expanding to 25.8%, showcasing effective cost management strategies amid inflationary pressures.
- Strong Medical Device Performance: The Medical Devices segment generated $5.675 billion in sales, a 12.3% increase, marking the 12th consecutive quarter of double-digit organic growth, with FreeStyle Libre sales reaching $2 billion, underscoring its market leadership.
- Nutrition Segment Challenges: The Nutrition segment saw an 8.9% decline in sales, primarily due to competitive pressures in the U.S. pediatric market, with management planning to regain market share through new products and promotional strategies, expecting growth in the second half of 2026.
See More
Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments
- Memory Supercycle: The Roundhill Memory ETF (DRAM) attracted over $5 billion in investments within a month, including $1.1 billion on Thursday alone, indicating strong market demand for memory stocks driven by surging AI computing needs.
- Core Holdings Performance: The ETF's core holdings feature leading memory manufacturers like SK Hynix, Micron, and Samsung, allowing investors to gain broad exposure to these high-growth companies, including those not listed on U.S. exchanges.
- Market Reaction: Micron's stock surged over 200 points in a week, climbing from $542 to $747, reflecting optimistic market expectations for memory product demand, with a price-to-earnings ratio of only 9 times projected earnings for the next 12 months, highlighting its appeal as a quality stock.
- Investment Opportunities: Despite waning interest in data center stocks, investors can still capitalize on potential gains in the memory and cooling sectors by purchasing instruments like the DRAM ETF, especially as major tech companies continue to invest heavily in data centers.
See More
Abbott Laboratories Shares Rise 1.75% After Six-Day Decline
- Stock Rebound: Abbott Laboratories (ABT) shares rose 1.75% to $87.81 in afternoon trading on Thursday, ending a six-day losing streak, indicating market expectations for a short-term recovery.
- Legal Pressure: The stock faced downward pressure after a Missouri appeals court upheld a $495 million verdict against the company, contributing to a 5.5% decline from April 29 to May 6, which adds to the legal overhang and may affect investor confidence.
- Analyst Ratings: According to Seeking Alpha's Quantrating system, Abbott is rated a hold with a score of 2.78 out of 5, achieving an A+ in profitability but a D in growth and momentum, highlighting challenges in its growth trajectory.
- Market Outlook: Despite a 14.9% decline over the past month and a 30% drop year-to-date, 21 out of 28 Wall Street analysts rate the stock as a buy or higher, suggesting ongoing confidence in its long-term value despite recent volatility.
See More
Dividend Stocks Comparison: Johnson & Johnson vs. AbbVie
- Diversification Advantage: Johnson & Johnson's diversified operations in pharmaceuticals and medical devices allow it to maintain stability in a competitive market, with revenue growth despite losing Stelara's patent, and it is projected to reach $100 billion in revenue by 2026, becoming only the second biopharma to achieve this milestone in history.
- Core Growth Drivers for AbbVie: AbbVie's leadership in immunology led to $15 billion in revenue in Q1, a 12.4% year-over-year increase, with Skyrizi and Rinvoq contributing $6.6 billion, showcasing strong market performance, though it faces competitive risks.
- Dividend Growth History: Johnson & Johnson has raised its dividends for 64 consecutive years compared to AbbVie's 54 years, indicating stronger financial stability and long-term investment appeal, particularly in the current market environment, with its AAA credit rating further enhancing its attractiveness as a low-risk investment.
- Market Risks and Opportunities: While Johnson & Johnson faces litigation risks related to its talc products, its diversified portfolio enables it to navigate challenges like drug pricing negotiations, whereas AbbVie shows potential in new product launches, especially with its weight-loss treatment performing well in clinical trials.
See More
Analysis of Dividend Stock Investment Opportunities
- McDonald's Stable Income: McDonald's has extended its dividend growth streak to 49 years with a 5% increase last year, and its current yield of 2.6% significantly exceeds the S&P 500's 1.1%, making it an ideal choice for income investors, while its 60% payout ratio provides flexibility for reinvestment.
- Procter & Gamble's Steady Performance: Procter & Gamble generated nearly $87 billion in sales over the past 12 months with an operating income of $20 billion, showcasing strong pricing power; despite being 5% from its 52-week low, its 2.9% yield and 70 years of dividend growth make it a quality asset for long-term holding.
- Abbott Laboratories' Growth Potential: Abbott has a 54-year dividend growth streak and has increased its payout by over 70% since 2020; despite a 30% drop in stock price this year, its acquisition of Exact Sciences positions it for leadership in oncology diagnostics, with a forecasted sales growth rate of at least 6.5%.
- Timing the Investment: With current economic conditions, McDonald's, Procter & Gamble, and Abbott are trading near their 52-week lows at 24 and 21 times earnings, indicating relatively cheap valuations and providing long-term investors with excellent buying opportunities.
See More
High Dividend Stocks Investors Should Focus On
- AbbVie Dividend Stability: AbbVie declared a quarterly cash dividend of $1.73 per share, and despite losing patent protection for Humira, the company has successfully achieved growth through strategic acquisitions and R&D investments, indicating a strong potential for continued dividends in the future.
- Significant Dividend Growth: Since its spin-off in 2013, AbbVie has increased its dividend by over 332%, with a 33% growth in the past five years, and a current dividend yield of 3.27%, which, although below historical averages, still reflects the company's robust profitability.
- Realty Income's Monthly Dividends: Realty Income, known as
See More
Abbott Laboratories Q4 2025 Financial Results Analysis
- Revenue Growth: Abbott reported total net sales of $11.459 billion in Q4 2025, reflecting a 4.4% increase, while organic growth reached 3.8% after excluding declining COVID-19 testing sales, indicating resilience in its medical device segment.
- Profitability Improvement: Adjusted diluted EPS rose 12% to $1.50, meeting market expectations, with operating margin expanding to 25.8%, showcasing effective cost management strategies amid inflationary pressures.
- Strong Medical Device Performance: The Medical Devices segment generated $5.675 billion in sales, a 12.3% increase, marking the 12th consecutive quarter of double-digit organic growth, with FreeStyle Libre sales reaching $2 billion, underscoring its market leadership.
- Nutrition Segment Challenges: The Nutrition segment saw an 8.9% decline in sales, primarily due to competitive pressures in the U.S. pediatric market, with management planning to regain market share through new products and promotional strategies, expecting growth in the second half of 2026.
See More
Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments
- Memory Supercycle: The Roundhill Memory ETF (DRAM) attracted over $5 billion in investments within a month, including $1.1 billion on Thursday alone, indicating strong market demand for memory stocks driven by surging AI computing needs.
- Core Holdings Performance: The ETF's core holdings feature leading memory manufacturers like SK Hynix, Micron, and Samsung, allowing investors to gain broad exposure to these high-growth companies, including those not listed on U.S. exchanges.
- Market Reaction: Micron's stock surged over 200 points in a week, climbing from $542 to $747, reflecting optimistic market expectations for memory product demand, with a price-to-earnings ratio of only 9 times projected earnings for the next 12 months, highlighting its appeal as a quality stock.
- Investment Opportunities: Despite waning interest in data center stocks, investors can still capitalize on potential gains in the memory and cooling sectors by purchasing instruments like the DRAM ETF, especially as major tech companies continue to invest heavily in data centers.
See More
Abbott Laboratories Shares Rise 1.75% After Six-Day Decline
- Stock Rebound: Abbott Laboratories (ABT) shares rose 1.75% to $87.81 in afternoon trading on Thursday, ending a six-day losing streak, indicating market expectations for a short-term recovery.
- Legal Pressure: The stock faced downward pressure after a Missouri appeals court upheld a $495 million verdict against the company, contributing to a 5.5% decline from April 29 to May 6, which adds to the legal overhang and may affect investor confidence.
- Analyst Ratings: According to Seeking Alpha's Quantrating system, Abbott is rated a hold with a score of 2.78 out of 5, achieving an A+ in profitability but a D in growth and momentum, highlighting challenges in its growth trajectory.
- Market Outlook: Despite a 14.9% decline over the past month and a 30% drop year-to-date, 21 out of 28 Wall Street analysts rate the stock as a buy or higher, suggesting ongoing confidence in its long-term value despite recent volatility.
See More
Dividend Stocks Comparison: Johnson & Johnson vs. AbbVie
- Diversification Advantage: Johnson & Johnson's diversified operations in pharmaceuticals and medical devices allow it to maintain stability in a competitive market, with revenue growth despite losing Stelara's patent, and it is projected to reach $100 billion in revenue by 2026, becoming only the second biopharma to achieve this milestone in history.
- Core Growth Drivers for AbbVie: AbbVie's leadership in immunology led to $15 billion in revenue in Q1, a 12.4% year-over-year increase, with Skyrizi and Rinvoq contributing $6.6 billion, showcasing strong market performance, though it faces competitive risks.
- Dividend Growth History: Johnson & Johnson has raised its dividends for 64 consecutive years compared to AbbVie's 54 years, indicating stronger financial stability and long-term investment appeal, particularly in the current market environment, with its AAA credit rating further enhancing its attractiveness as a low-risk investment.
- Market Risks and Opportunities: While Johnson & Johnson faces litigation risks related to its talc products, its diversified portfolio enables it to navigate challenges like drug pricing negotiations, whereas AbbVie shows potential in new product launches, especially with its weight-loss treatment performing well in clinical trials.
See More
Analysis of Dividend Stock Investment Opportunities
- McDonald's Stable Income: McDonald's has extended its dividend growth streak to 49 years with a 5% increase last year, and its current yield of 2.6% significantly exceeds the S&P 500's 1.1%, making it an ideal choice for income investors, while its 60% payout ratio provides flexibility for reinvestment.
- Procter & Gamble's Steady Performance: Procter & Gamble generated nearly $87 billion in sales over the past 12 months with an operating income of $20 billion, showcasing strong pricing power; despite being 5% from its 52-week low, its 2.9% yield and 70 years of dividend growth make it a quality asset for long-term holding.
- Abbott Laboratories' Growth Potential: Abbott has a 54-year dividend growth streak and has increased its payout by over 70% since 2020; despite a 30% drop in stock price this year, its acquisition of Exact Sciences positions it for leadership in oncology diagnostics, with a forecasted sales growth rate of at least 6.5%.
- Timing the Investment: With current economic conditions, McDonald's, Procter & Gamble, and Abbott are trading near their 52-week lows at 24 and 21 times earnings, indicating relatively cheap valuations and providing long-term investors with excellent buying opportunities.
See More
High Dividend Stocks Investors Should Focus On
- AbbVie Dividend Stability: AbbVie declared a quarterly cash dividend of $1.73 per share, and despite losing patent protection for Humira, the company has successfully achieved growth through strategic acquisitions and R&D investments, indicating a strong potential for continued dividends in the future.
- Significant Dividend Growth: Since its spin-off in 2013, AbbVie has increased its dividend by over 332%, with a 33% growth in the past five years, and a current dividend yield of 3.27%, which, although below historical averages, still reflects the company's robust profitability.
- Realty Income's Monthly Dividends: Realty Income, known as
See More
